Manic-depressive illness is a common psychiatric disorder with complex etiology that likely involves multiple genes and non-genetic influences. The uncertain path to gene discovery has spurred considerable debate over genetic findings and gene-finding strategies. In this article, I review the main findings, with a focus on: (1) putative linked loci on chromosomes 1q31-32, 4p16, 6pter-p24, 10p14, 10q21-26, 12q23-24, 13q31-32, 18p11, 18q21-23, 21q22, 22q11-13, and Xq24-28; and (2) association studies with candidate genes, dynamic mutations, mitochondrial mutations, and chromosomal aberrations. Although no gene has been identified, promising findings are emerging. I then discuss the challenges and opportunities ahead, with special emphasis on gene-finding methods-in particular, questions pertaining to phenotype definition, linkage and association mapping, gene markers, sampling, study population, multigene systems, lessons from other disorders, animal models, and bioinformatics. The progress to date, together with rapid advances in genomics, analytical and computational methods, and bioinformatics, holds promise for new insights into the genetics of manicdepression, in the new millennium.
state-of-the-art. Progress in unraveling the genetic complexity has been slow, a familiar pattern in complex, non-mendelian disorders. Here I offer an overview of genetic findings and gene-finding strategies, with a view toward future research. With rapid advances in genomics, bioinformatics, and analytical and computational tools, there are important implications for genetic studies of BP.
Early strides
Early efforts to probe the genetic underpinnings of BP employed three main strategies: (1) segregation analysis, testing the statistical fit of observed transmission patterns to specific genetic models (eg, single-majorlocus, oligogenic, and multifactorial-polygenic inheritance); (2) studies of genetic vulnerability traits, or biological endophenotypes (eg, neurotransmitter receptors, enzymes, or metabolites; and psychoactive drug binding sites or transfer across cell membranes); (3) linkage studies with 'classical', or phenotypic gene markers (eg, leukocyte antigens, blood groups, or serum proteins).
Despite extensive efforts, the genetics of BP proved unyielding. Although some segregation analyses advocated a role for single-locus inheritance, 1, 2 results in general are not consistent with this mode of transmission. Oligogenic and multifactorial-polygenic models are more plausible alternatives 3, 4 but are indistinguishable in terms of statistical fit to the data.
Likewise studies of genetic vulnerability traits and classical gene markers have been inconclusive, undermined by the low prior probability of selecting the 'right' vulnerability trait as a tenable candidate, and by the paucity and low information content of available gene markers. 5 The identification of polymorphic DNA markers heralded a new era in human genetics. These markers, which scored early successes in mapping genes for mendelian disorders, were recognized early on in psychiatric genetics 6, 7 and were promptly applied to BP. Using two DNA markers on chromosome 11p-insulin (INS) and Ha-ras-1 (HRAS1), Egeland et al 8 reported a lod score of 4.9 in a large Old Order Amish pedigree. They concluded tight linkage between BP and HRAS1, and proposed that the gene for tyrosine hydroxylase is a potential candidate gene by virtue of its location in the INS-HRAS1 region. However, this high-profile study, which engendered hopes for prompt genetic dissection of BP, endured a reversal of fortune: a subsequent extension and reanalysis of these data resulted in substantially reduced evidence of linkage. 9 The result of the follow-up study was attributed to changes in diagnosis due to new illness onset, ambiguous or uninformative marker status in the original analysis, and newly studied pedigree branches with no evidence of linkage. Likewise, subsequent studies gave no clear indication of linkage to this region, in other populations.
The lessons from this study were reinforced by the reevaluation of another notable finding: the reported linkage between BP and classical markers colour blindness and glucose-6-phosphate dehydrogenase (G6PD) deficiency, on chromosome Xq. This finding, which dates to the premolecular era, was reported in several independent studies (see Baron 10 for review). However, on reanalysis of some of these data using multiple DNA markers, reassessment of phenotypes, and extension of pedigrees, the overall evidence of linkage was markedly reduced. 11 DNA marker studies in other populations did not show linkage to this genomic site. Similarly, a report of significant linkage between BP and a DNA marker at the F9 locus, also on chromosome Xq (though at a more proximal location), 12 was not confirmed in most other pedigree series.
Recent findings
The heightened awareness of uncertainties in genetic analysis of complex psychiatric disorders has led to methodological improvements. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Together with progress in the genetic mapping of other complex disorders (eg, diabetes mellitus, Alzheimer disease, breast cancer, and colorectal cancer), the advances in research methods have invigorated psychiatric genetics, prompting a new harvest of findings. Results are compiled in the World Congress on Psychiatric Genetics chromosome workshops. [23] [24] [25] Here I focus on 'promising' results, as judged by statistical significance, support from other studies, or other potential insights into the genetics of BP. However, as Molecular Psychiatry with other complex traits, conflicting results abound [23] [24] [25] and criteria for 'significance' or genetic relevance are not well established. For these reasons, 'promising' findings are merely hypothesis generating, and results that seem of lesser interest need not be discarded (see also Opportunities and Challenges below). The results are grouped in two categories: linkage studies and association studies.
Linkage studies
Linkage studies are mainly concerned with reversegenetics: testing anonymous DNA markers-usually in the context of a genome-wide scan-for cosegregation with the disease in families. Candidate genes can also be studied, though their role in linkage studies is largely limited relative to association studies (see Association Studies below). Commonly used disease phenotypes are BPI, a 'narrow' disease definition consisting of manic syndromes (mainly bipolar I disorder, or mania and depression); BPII, an 'intermediate' disease phenotype comprised of BPI and bipolar II disorder (hypomania and depression), and BPIII, a 'broad' disease definition, which includes BPII and recurrent depressive syndromes. Family configurations typically include extended multiplex pedigrees or smaller, sibpair families.
'Significant' or 'suggestive' evidence of linkage (see Linkage Methods below) has been reported in several chromosomal regions: 1q31-32, 4p16, 6pter-p24, 10p14, 10q25-26, 12q23-24, 13q31-32, 18p11, 18q21-23, 21q22, 22q11-13, and Xq24-28.
Chromosome 1q31-32 Detera-Wadleigh et al 26 reported suggestive linkage to 1q31-32 in a genomewide scan of 22 US pedigrees. Using affected-sib-pair (ASP) analysis, they found a multipoint lod score of 2.67 (P = 0.00022) under BPI, with support from parametric linkage analysis (lod score Ͼ2 at marker GATA124F08 under a dominant model). Interest in this region also stems from the reported association between BP and a fragile site at 1q32, 27 and from a report of linkage to schizophrenia (see BP-Schizophrenia Overlap below).
Chromosome 4p16 Blackwood et al
28 observed a multipoint lod score of 4.8 in a large Scottish pedigree. The maximum lod score occurred at region D4S431-D4S403, under BPI and BPII and a dominant model. There was evidence of linkage heterogeneity when a further 11 pedigrees from the same population were analyzed, but no support for linkage to several candidate genes in the region, including the genes for the dopamine D5 receptor (DRD5), a GABA receptor (GABRB1), and Wolfram syndrome (WFS1). 28 Support for linkage to this region was also reported by DeteraWadleigh et al 26 (multipoint lod score of 1.77 using ASP analysis under BPIII) and Polymeropoulos and Schaffer 29 (a lod score of 1.68 under a dominant model and BPII), in US pedigrees, and by Ewald et al 30 (a lod score of 2.0 under a recessive model and BPIII), in Danish pedigrees. Interestingly, a putative locus for mental health 'wellness' was also mapped to 4p16 in Old
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Order Amish multiplex pedigrees, suggesting that alleles at this locus could modify the expression of the disease. 31 Chromosome 6pter-p24 In a linkage study of a large Old Order Amish pedigree complex, Ginns et al 32 reported a lod score of 2.47 at D6S7 under the BPII disease phenotype and a dominant model. ASP analysis gave a P-value of 0.0003 at the same locus, but weighting for the number of meioses resulted in marginal support (P = 0.029). In an independent study of a subset within the same Amish pedigree, Polymeropoulos and Schaffer 29 found a lod score of 3.12 at D6S344, in the same general region, under the BPI diagnostic model and dominant inheritance. Because this finding originated from a subset of the pedigree analyzed by Ginns et al, 32 it does not constitute a bona fide confirmation, though the use of a different set of markers analyzed separately provides a measure of support. An earlier study using classical markers 33 was also consistent with linkage to 6pter. 34 reported a lod score of 2.5 near D10S1423 in 97 US families, suggesting linkage to BPII using affected relative pair methods. An earlier analysis of this pedigree set, using ASP methods, was also supportive of linkage to BPI and BPII, with respective MOD scores of 2.04 and 3.4 (P Ͻ 0.01). 35 The reported linkage to schizophrenia contributes to the interest in this region (see BP-Schizophrenia Overlap below). 42 However, a recent study 43 using mutational screening showed no evidence for the involvement of this gene in BP.
Chromosome 10p14 Foroud et al

Chromosome 10q25-26
Chromosome 13q31-32
In their ASP analysis of 22 US pedigrees, Detera-Wadleigh et al 26 observed a lod score of 3.5 (P = 0.000028) at the D13S1252-D13S1271, under BPIII. Similar results were obtained using narrower disease definitions. In a study of 20 US pedigrees, Kelsoe et al 37 obtained lod scores over 2 for D13S225 (using BPII) and D13S796 (using BPIII), under a dominant model. Modest support for linkage using ASP analysis was also provided in another series of US pedigrees. 44 The reported linkage to schizophrenia is a further source of interest in this region (see BP-Schizophrenia Overlap below).
Chromosome 18p11
In an update of previous results, 45 Berrettini et al 46 reported multilocus ASP results suggestive of linkage at D18S62-D18S40 (P Ͻ 0.00008) under BPIII, in 22 US pedigrees. The multipoint affected-pedigree-member results were also consistent with linkage to this region (P Ͻ 0.00001). Linkage appeared to be confined to pedigrees with paternal transmission (pedigrees in which the illness appears to be transmitted from the paternal side). 47 Stine et al 48 reported increased allele sharing for 18p11 markers, in particular D18S37 (P Ͻ 0.0003), in a separate series of 28 US pedigrees; however, a reevaluation of the data, using multilocus ASP analysis with adjacent markers, did not produce evidence of linkage. 49 In a study of 57 German families, Nothen et al 50 observed a lod score of 2.54 at D18S37, D18S453, and D18S40, under a recessive model and BPI, in families with paternal transmission; ASP analysis gave marginal support for linkage in these pedigrees. This region is of interest because it harbors Golf, a G-protein receptor gene and a candidate gene for BP. Evidence of linkage in schizophrenia pedigrees is also a focus of interest (see BPSchizophrenia Overlap below).
Chromosome 18q21-23
In a study of 28 US families, Stine et al 48 reported excess allele sharing for several markers on 18q21-22, especially D18S41, using ASP analysis (P = 0.0004). The evidence was strongest in 'paternal' pedigrees under BPIII: P = 0.00002 using ASP analysis, and a lod score of 3.51 under a dominant model. The same group 51 reported excess allele sharing by ASPs (P = 0.0003), in a new sample of 30 US families, though at a marker (D18S541) considerably distant from D18S41, and in 'maternal' rather than 'paternal' families. Freimer et al 52 65 reported a lod score of 3.54 at DXS994 under a dominant model and BPII, and an association with a distinct haplotype on Xq24-27.1. The coding region of HPRT, a potential candidate gene mapped to Xq26, was sequenced, with no evidence for sequence variations associated with BP. In addition, the investigators reanalyzed previously published data on Xq24-27 and BP; a lod score of 2.78 at DXS51 was found in the combined analysis, with weaker signals at F9, on Xq27.
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They concluded that the combined data support linkage to Xq26. Earlier studies found support for linkage to F9 in Belgian pedigrees 12 and in a single French pedigree. 66 As mentioned (see Early Strides above), some of the early evidence for linkage to Xq28 was greatly reduced on follow-up of the original findings. However, a recent study by Bocchetta et al, 67 with evidence for excess maternal transmission of BP in males carrying the G6PD-Mediterranean mutation, has renewed interest in a possible role for Xq28.
Association studies
Association studies of BP involve candidate genes, dynamic mutations, mitochondrial mutations, and chromosomal aberrations. Arbitrary gene markers can also be studied, though typically in regions of interest detected by linkage analysis (see Challenges and Opportunities, below).
Candidate
genes The candidate-gene strategy employs forward-genetics: testing gene markers with presumed functional relevance for the disease (eg, genes that encode neurotransmitter enzymes or receptors). These studies examine the co-occurrence of a marker and disease using either a case-control design (unrelated cases vs population-based controls) or a family-based design (eg, a trio consisting of an affected child and two parents, as controls).
Most association studies involve genes implicated in serotonergic, dopaminergic, and noradrenergic systems. Interest in these systems stems from their apparent role in regulating mood and behaviour, also evident from the presumed mode of action of drugs for the treatment of BP. There are numerous such studies, with contradictory results. [23] [24] [25] Because association studies are primarily geared toward genes of modest effect, studies of sizeable, statistically powerful samples may yield more meaningful results than the more typical small-scale studies. Three such studies, which sought to evaluate previous conflicting data on two of the beststudied candidate genes for BP-tyrosine hydroxylase (TH) and tryptophan hydroxylase (TPH), are described below. Other, small-scale studies were reviewed elsewhere. [23] [24] [25] Turecki et al 68 reported a meta-analysis of published association studies of BP and TH gene markers. The studies were identified by means of computerized searches of databases, and the scanning of articles and reference lists. Their combined sample consisted of 1069 subjects (547 cases and 522 normal controls). There was no overall association between BP and TH polymorphisms in this sample.
Souery et al 69 conducted a European multicenter case-control study involving 802 subjects (401 BP patients and 401 matched controls) and a tetranucleotide polymorphism in the TH gene. To account for phenotypic heterogeneity, they performed subgroup analyses with several variables such as age at onset, family history, and diagnostic stability. No association was found in the total sample or in the subgroups examined.
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The same research group, 70 using a similar multicenter design, studied the TPH A218C polymorphism in 927 cases (527 BP patients and 400 patients with major depression) and their matched controls. No association was found with the TPH polymorphism in either patient group, nor was there evidence for association when patients were subgrouped based on presence or absence of suicidal behaviour.
Dynamic mutations Dynamic mutations, or expanded trinucleotide repeat sequences (unstable DNA repeats that increase in size across generations), are implicated in disorders that display 'anticipation' (increase in disease severity, or decrease in age-at-onset, in successive generations) and imprinting (parent-of-origin effect on disease transmission). Such disorders include fragile-X syndrome and Huntington's disease. Since 'anticipation' and parent-of-origin effect have been observed in BP (reviewed in O'Donovan and Owen 71 ), studies utilizing repeat expansion detection (RED) are of interest.
An association between BP and unstable repeat sequences was reported in several studies using the RED method (eg, Lindblad et al, 72, 73 O'Donovan et al, 74, 75 Oruc et al 76 ). However, not all studies agree and larger data sets may be needed. Also, 'anticipation' and parent-of-origin effect have not been observed consistently in BP, and ascertainment bias has been invoked as a possible explanation. 71, 77 Mitochondrial mutations Reports of preferential transmission of BP through the maternal line 47, 78 are consistent with mitochondrial inheritance, since mitochondria are largely maternally inherited. There are several anecdotal reports of subjects with BP or other affective disorders, who also show mitochondrial abnormalities. 79, 80 Kirk et al 81 employed a more systematic approach to this question by way of sequencing the mitochondrial genome in a series of BP patients with matrilineal inheritance of psychiatric disorders. No polymorphism detected in this sequencing showed significant association with BP, using a case-control design. However, there were fewer closely related haplotypes in the BP group than in the matched controls, suggesting a role for low-penetrance mitochondrial DNA variants in BP. The evidence is merely suggestive and more study is needed. Also, the reported excess of maternally transmitted disease 47, 78 has not been observed in other studies, raising questions of ascertainment or other methodological uncertainties. 71, 77, 82 Chromosomal aberrations Chromosomal abnormalities may help in gene discovery by flagging candidate regions for further study. There are numerous reports of associations between BP and chromosomal abnormalities, including translocations, deletions, insertions, trisomies, and fragile sites. Craddock and Owen 83 reviewed earlier reports and identified four genomic regions of interest, using a modification of the relevancy criteria proposed by Bassett:
84 chromosomes 11q21-25 (balanced translocation), 15q11-13 (deletions), 21q22 (Down's syndrome trisomy), and Xq27-28 (fragile X). Of these regions, 21q22 and Xq27-28 hold special interest in light of possible linkage to BP (see Linkage Studies above).
Recent reports point to two other regions of interest: chromosomes 1q31-32 (a fragile site 27 ) and 22q11-13 (deletions involved in the velo-cardio-facial syndrome, which maps to this region). As mentioned (see Linkage Studies above), there are accounts of linkage between BP and these regions.
The great majority of the chromosomal aberrations implicated in BP are likely chance events because of the high prevalence of the disease, and the fact that most of the reported aberrations were observed in isolated cases. However, the finding of independent evidence of linkage between BP and some of these regions (ie, 1q31-32, 21q22, 22q11-13, and Xq27-28) is of interest and warrants further study.
Challenges and opportunities
Notwithstanding methodological advances and a crop of intriguing findings, the myriad conflicting results, the limited power to detect and replicate gene effects, and difficulties in sorting out true-positive from falsepositive results, pose a challenge to genetic studies of BP. Following is a summary of methodological issues, with a view to future directions.
The Phenotype
Uncertainties in phenotype definition stem from: (1) the considerable variability in clinical manifestations; and (2) lack of external validating criteria (eg, biological correlates of genetic relevance). Strategies that aim to address this issue include use of clinical subtypes, polydiagnostic approaches, search for endophenotypes, and lessons from genetic commonality with other disease-states.
Clinical subtypes Dissection of the phenotype to subtypes may reduce heterogeneity and pinpoint clinical forms with distinct genetic mechanisms. As mentioned (see Linkage Studies above), commonly used BP phenotypes range from narrow to broader disease definitions. Thus, for example, if one were to assume a relatively rare, dominant allele for the narrowest (and least common) disease phenotype (BPI), then a linked marker would yield greater statistical significance under BPI than the broader (and more common) BPIII; also, the significance should be more pronounced using parametric lod score methods than ASP analysis. Likewise, if the disease allele is common, recessive and confers susceptibility to a broad disease phenotype (eg, BPIII), one would expect the ASP results under BPIII to be more significant than parametric lod score analysis under a dominant model and BPI. BPI is thought to display greater homogeneity and a more predictable genotype-phenotype relationship than the broad 'variants' of the BP phenotypic spectrum. However, a review of the evidence (see Linkage Studies) suggests a complex picture, with positive results under various configurations of genetic models and disease phenotypes. This may be partly attributable to complex inheritance or variable statistical power across studies (for example, in most pedigree samples, BPI is less prevalent than broader disease phenotypes, leading to weaker linkage signals where linkage may truly exist).
Pharmacogenetics is another possible approach to reducing phenotypic heterogeneity. Turecki et al 85 reported an allelic association study of Golf and adjacent markers, in responders to lithium prophylaxis. Golf is mapped to 18p11, where evidence of linkage to BP has been reported (see Linkage Studies). Since lithium is known to impair G-protein activation, Golf is a potential candidate gene. However, there was no evidence of association with any of the loci examined. This suggests that response to lithium may not be a promising phenotypic indicator in this instance, or that 18p11 does not harbor an easily replicable gene effect. In contrast, Alda et al 62 showed support for linkage between BP and 21q22, another region implicated in BP (see Linkage Studies), in families ascertained through patients with a favorable response to lithium therapy. Lithium responsive BP has also shown possible association or linkage to the phospholipase C gene 86 and a chromosome 15 region. 87 It remains to be seen if defining the phenotype as a dichotomous (all-or-none) trait will yield more consistent results. There is considerable variability across studies, and other dichotomies of interest, eg, early vs late illness onset, rapid cycling BP (high-frequency episodes) vs lower-frequency subtypes, 'seasonal' BP (season-related episodes) vs other disease types, and presence vs absence of psychosis or co-morbidity, have not been studied systematically.
Polydiagnostic approaches There are different sets of diagnostic criteria for BP currently in use, such as the research diagnostic criteria (RDC), the International Classification of Diseases (ICD10), and the Diagnostic and Statistical Manual (DSM IV). Although reliability is usually established, the 'biological validity' of the different approaches is not known, and this presents difficulties when sets of criteria differ. A polydiagnostic approach, heeding competing diagnostic systems, could redress this problem. Computerized methods that can facilitate this task are available. 88 However, polydiagnostic approaches, especially in conjunction with the commonly used clinical subtypes (see above), could further compound the multiple testing problem, which already confounds genetic analyses of psychiatric disorders. Also, the disparity among commonly used criteria for BP may not be sufficiently striking as to reflect differences in the underlying biological construct.
Endophenotypes Endophenotypes are continuous (as opposed to dichotomous) phenotypes, which can be derived using symptom-based algorithms or biological characteristics. Such quantitative measures may be more closely related to the underlying genetic vulnerMolecular Psychiatry ability than discrete clinical phenotypes. They may also provide greater statistical power to detect gene effects.
There have been several attempts to address this issue. For example, Rice et al 89 proposed a quantitative 'caseness index' (the probability of a case being true, as a function of illness severity and diagnostic stability), subsequently applied by Baron et al 90 in a reanalysis of linkage data, with no appreciable impact on the original results (obtained using dichotomous phenotypes). Similarly, Turecki et al 91 reanalyzed linkage data using quasi-quantitative (risk weighted by severity), liabilitybased (penetrance ratios), and traditional discrete phenotypes, with no evidence that any model performed consistently better than the others. Van Eerdewegh et al 92 and Levinson 93 explored probabilistic, liability-based, weighting of BP phenotypes, with no clear evidence as to the relative performance of linkage strategies, under the models tested.
Biological endophenotypes are heritable diseaserelated traits, which are also present in unaffected relatives (see Early Strides). Integration of such traits in genetic analysis of BP has yet to show clear promise.
There is more evidence of putative biological phenotypes of genetic relevance in schizophrenia, in particular eye tracking abnormalities, P50 sensory gating deficit, and a composite biological phenotype-combining the P50 sensory gating and antisaccade ocular motor performance (reviewed in Baron 94 and Leal 95 ). The latter biological trait may also be relevant to BP by virtue of possible linkage to chromosome 22q11-12, 96 a region implicated in both BP and schizophrenia (see BP-Schizophrenia Overlap below). There is, in addition, evidence from neuropsychology, neuroimaging, and neuroanatomy, that other potential endophenotypes may be in play. For example, BP-related impairments have been observed on conventional neuropsychological tests, and neuroimaging studies suggest that the medial and orbitofrontal cortex, regions that underlie cognitive processing of affective content, may be involved in BP and depression (reviewed in Murphy and Sahakian 97 ). There is, in addition, evidence from neuroanatomical studies that subtle structural brain abnormalities-in particular, smaller basal ganglia and higher neuron density in the locus ceruleus-may also contribute to the pathogenesis of BP and related mood disorders (reviewed in Baumann and Bogerts 98 ). More study is required to establish if these putative endophenotypes are bona fide genetic vulnerability traits.
These attempts are limited to specific scenarios. More systematic searches for endophenotypes relevant to the genetics of BP are needed.
BP-schizophrenia overlap Although BP and schizophrenia are generally viewed as distinct nosological entities, with no significant coaggregation in families, there is evidence for overlap. [99] [100] [101] [102] For example, relatives both of BP and schizophrenic patients are at increased risk for schizoaffective disorder (a condition combining affective and schizophrenic features) and major depression. Also, relatives of schizoaffective patients show increased rates of BP, major depression, and schizophrenia. Additionally, there is some commonality in clinical and epidemiological features: the two disorders have some common psychotic features, are lifelong conditions, show no gender differences, and have similar population prevalence and age-atonset distribution.
Reports that the two disorders may have susceptibility genes in common (reviewed in Berrettini, 103 Baron 94 and Linkage Studies above) is consistent with the notion of a BP-schizophrenia overlap. In particular, chromosomes 1q32, 10p11-15, 13q32, 18p11, and 22q11-13, which were linked to BP in some studies, have also been implicated in schizophrenia. (P = 0.009), both in US families.
Evidence of shared susceptibility genes may provide cross-validation of genetic findings and a basis for exploratory analyses using a broader definition of the disease phenotype.
Linkage methods
Debatable issues include sample composition (extended multiplex pedigrees vs nuclear sib-pair families), type of analysis (model-based, or parametric analysis vs model-free, or nonparametric analysis), transmission patterns, marker characteristics (density, or marker spacing, and informativeness), sample size, and definition of statistical significance. 4, 19, [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] The basic issues, which have a bearing on study design and interpretation of results, can be summarized as follows:
Sample composition Early studies were largely based on extended multiplex pedigrees. Critics (and advocates of nuclear sib-pair families) have argued that extended pedigrees show: (1) reduced power for linkage detection due to intrafamilial heterogeneity caused by 'extraneous genes' introduced by marrying-in spouses (assuming common disease alleles); and (2) bias in favor of single-gene, dominant-like inheritance (especially in unilineal pedigrees). Others, however, argue that: (1) small sib-pair families are also susceptible to intra-familial heterogeneity (phenocopies may be more common due to low illness density); (2) extended pedigrees contain more genetic information than small families, and this may offset potential loss in power due to heterogeneity; also, some of the intrafamilial heterogeneity could be accounted for by splitting the extended pedigrees into their component nuclear families (though not without some loss of information); (3) the dominant-like appearance of some extended pedigrees does not imply that alternate genetic models (eg, oligogenes) cannot be explored as well; also, detection of 'dominant', larger-effect genes might have a greater biological significance than genes of modest effect.
Positive findings (Linkage Studies, above) were obtained using various sample compositions, suggesting that neither ascertainment scheme has a clear-cut advantage over the other.
Type of analysis Earlier studies favoured modelbased ('parametric'), classical lod score analysis. Detractors have argued that this method is not well suited for complex disorders such as BP because, unlike model-free ('nonparametric') methods, it requires specification of mode of inheritance. It has been shown, however, that model-based methods: (1) are largely robust to model misspecification, if more than one model is tested; this also allows for the testing of different models (eg, dominant vs recessive), covering a range of genetic hypotheses; and (2) may have greater power than model-free methods when employed under different sets of genetic assumptions and corrected for multiple testing. Also, the dichotomy of model-based vs model-free analyses has been overstated. For example, ASP analysis (the most commonly used model-free method) is statistically equivalent to a recessive lod score analysis (a model-based method). Similarly, parametric lod scores may actually be nonparametric, if only one genetic model (whether correctly or incorrectly specified) is tested.
The studies reviewed earlier (Linkage Studies, above) indicate that positive findings were obtained using both model-based and model-free analyses, and that these methods often complement each other. This suggests that both methods can be useful for linkage detection.
Transmission patterns Distinct patterns of disease transmission are a potentially useful tool in dissecting the inheritance of complex traits. Early attempts focused on sex-linked transmission in BP (reviewed in Baron 10 ). The hallmarks of X-linked dominant inheritance-paucity of father-son transmission and preponderance among women-were observed in early family and epidemiological studies and led to a series of linkage studies with X-chromosome markers. However, subsequent studies did not support gender differences consistent with sex-linked inheritance, and presumed X-linked cases comprise a small minority, at best (see also Linkage Studies).
The finding of genomic imprinting and mitochondrial transmission in humans has revived the search for gender-dependent transmission (parent-of-origin effects), in a further effort to dissect the inheritance of BP. Some studies showed that linkage to chromosomes 18p11 47, 48, 50 and 18q21-23 48 is more pronounced under paternal transmission, and that pedigrees with maternal transmission are preferentially linked to chromosome 21q22. 58 However, other studies produced contradictory or equivocal results, 50,51,57,77,125-127 raising uncertainties about the detection and interpretation of parent-of origin effects (see also Dynamic Mutations and Mitochondrial Mutations, above).
Marker characteristics Marker-to-marker intervals in most genome scans of BP are 10-20 cM. This marker spacing is believed to be cost-effective for linkage detection. However, since not all regions of the genome are equally covered (leaving gaps in marker coverage), and since not all markers are highly informative, true linkages may elude detection. For example, evidence for linkage between BP and 21q22, using dense marker coverage (Ͼ2 cM), was missed entirely in a 10 cM genome scan done separately on the same pedigree series, because the marker nearest to the locus which showed the highest lod score in the high-density study was 8 cM away. 36 Consistent with this observation, other researchers 26 showed that scans utilizing marker coverage denser than earlier searches in the same pedigree set (6 cM vs 10-12 cM) gave more consistent support for linkages reported independently by other groups. These observations suggest that variability in marker density and informativeness should be taken into account in the interpretation of linkage findings.
Statistical significance What constitutes appropriate thresholds for statistical significance in studies of complex disorders is a matter of debate. What appears to be 'significant linkage' under one set of criteria could eventually be proven a false-positive, even in the presence of independent 'replication'. Conversely, linkage results that do not quite meet criteria need not be ignored, lest a true gene effect may go undetected.
This notwisthanding, widely used guidelines for genome-wide significance of linkage results have been proposed, based on simulations. 19 Thus, 'significant' linkage refers to statistical evidence expected to occur 5% of the time (or once in 20 genome scans); evidence of 'suggestive' linkage would occur one time at random in a genome scan. The categories of 'significant' and 'suggestive' linkage under parametric analysis correspond to lod scores of 3.3 and 1.9, respectively. The corresponding lod scores in ASP analysis are 3.6 and 2.2 (pointwise P values of 0.000022 and 0.00074, respectively). For studies involving affected-pedigreemember analysis, the corresponding pointwise P values are 0.00005-0.00001 and 0.005-0.0001. Once significant linkage is declared, a P value of 0.01 in an independent sample is required for replication.
With these guidelines in mind, most of the putative linkages for BP (see Linkage Studies) are at the 'suggestive' level. Some of the results surpass the 'significance' threshold, with evidence of potential replication. Interpretation of these findings depends on whether or Molecular Psychiatry not the chosen statistical criteria are viewed as too stringent or too liberal.
Association methods
The growing appeal of linkage disequilibrium studies has led to myriad analytical methods, with varying degrees of complexity. These include two-locus analysis, transmission disequilibrium test (TDT), haplotype relative risk (HRR) analysis, multilocus likelihood measures, and haplotype segment sharing methods. As reviewed, 128 each of these techniques has its pros and cons, with implications for the design and interpretation of association studies.
For example, the commonly used two-locus method, used primarily in case-control studies, is easy to apply but is strongly influenced by marker allele frequencies (resulting, for example, from population stratification). TDT, often used in family-based designs, is unaffected by population stratification but is less efficient than the standard two-locus approach; it can use only heterozygous parental genotypes. HRR analysis can estimate allele frequencies from both homozygous and heterozygous parental genotypes (making it useful for DNA pooling), but is susceptible to population stratification (can lead to false-positive results). Multilocus likelihood methods consider multiple markers, augmenting the power to detect linkage disequilibrium. Also, these methods accommodate multiple mutations at marker and disease loci and can allow the pooling of heterogeneous data from multiple studies. However, covariance among markers is not taken into account and there are some limiting assumptions. Haplotype segmentsharing methods analyze haplotype regions shared in affected cases, taking into account the relationships among marker groups (ie, the covariance structure of marker loci). These methods may have greater power than the other methods to detect disease mutations under moderate heterogeneity, but they may be compromised by allelic heterogeneity.
Association vs linkage
Although most gene mapping efforts employ linkage methods, association studies with candidate genes are gaining momentum. This trend stems from the view that linkage studies are of limited utility because of: (1) inconsistent results; (2) complex inheritance governed by genes of modest effect, which are not amenable to the linkage approach absent samples of 'unrealistic' size, and (3) the substantial cost and labor incurred in genome-wide linkage studies, as compared to association studies with a few candidate genes selected on the basis of 'plausible' neurobiological formulations (see Candidate Genes, above).
There are caveats, however. [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] First, inconsistent results are at least as common in association as in linkage studies (see Association Studies, above). Second, genes of modest effect have been detected by linkage analysis, in other complex disorders. For example, HLA, which is implicated in type I diabetes, 139 and APOE, which predisposes to both late-onset Alzheimer's disease and cardiovascular disease. 140 Simula-tions suggest that oligogenic models (a genotypic relative risk of 2 per disease locus) may explain the inheritance of complex disorders such as BP, and that linkage analysis might detect the genes involved in samples of 'realistic' size. 4 Third, the infinitesimal odds of selecting a likely candidate gene-given limited knowledge of pathophysiology and the multitude of genes expressed in the brain-would require substantially stricter statistical thresholds and samples far larger than those commonly reported, to counter spurious associations. [131] [132] [133] Statistical artifacts arising from population stratification due to ethnic variation is a further complication, especially in commonly used case-control designs (see Association Studies, above).
Recently, genome-wide, large-scale association studies have been proposed, as an alternative to the conventional candidate-gene approach. 141, 142 Arguments in favor of this approach include: (1) systematic examination of all potential candidate genes; (2) adequate power to detect genes with genotypic relative risks as small as 1.5 and allele frequencies as high as 0.70 (parameters thought to characterize complex diseases such as BP); (3) use of attainable, 'realistic' samples, as opposed to the vastly larger samples required for linkage analysis, assuming similar parameters; and (4) the fact that candidate regions identified through linkage studies are often intractably large for effective positional cloning. There are, however, reasons for caution. [143] [144] [145] For example, uncertainties over appropriate statistical guidelines given the vast number of permutations; the possibility that sufficient power to detect modest gene effects may never be achieved, in case of substantial allelic heterogeneity; perturbation of the relationship between association and inter-locus physical distance due to historical events (eg, admixture, multiple mutations, and genetic drift), and questions about the effective use of gene markers (see Gene Markers, below).
Combining linkage and association analyses could be more advantageous than a dichotomous approach. For example, inconclusive evidence for linkage or association (obtained in independent analyses) could be augmented by a joint linkage and association study, as has been shown for: (1) a gene for psoriasis, on chromosome 6p21; 146 and (2) the type 1 angiotensin II receptor locus, a candidate gene for essential hypertension. 147 A two-stage, sequential approach can also be employed, whereby an initial genome-wide scan, using linkage analysis, is followed by association studies of all plausible candidate genes in regions with evidence of linkage. 137 Although some genes of modest effect may be missed in the initial scan, this strategy is more costefficient than a comprehensive whole-genome association analysis.
Gene markers DNA markers have emerged in stages. They include restriction-fragment-length polymorphisms (RFLPs), variable-number-tandem-repeats (VNTRs), and microsatellite markers. The latest installment in this progression, an outgrowth of the Human Genome Project, is single-nucleotide polymorphisms, or SNPs.
SNPs SNPs arise from single-base mutations, which substitute one nucleotide for another. As reviewed, [148] [149] [150] SNPs have many distinct advantages over other types of polymorphisms, or gene markers. These advantages, which can be exploited in the search for complex disease genes, include: (1) Abundance (hundreds of thousands of SNPs appear in public databases), which allows high-density gene mapping studies on a scale larger and more intensive than previous efforts. The abundance of SNPs can increase the power of resolution of gene mapping. It may also create haplotypic diversity that can be exploited in both linkage mapping and direct association (or linkage disequilibrium) studies. (2) Extensive presence throughout the genome, including exons, introns, promoters, and enhancers. Thus, exonic SNPs may have direct relevance to functional proteins, intronic SNPs could impact splicing, and SNPs found in promoters and enhancers could influence gene expression. (3) Less mutability compared to other polymorphisms, allowing greater reliability in assessing co-segregation and locus associations across generations. (4) Promise of rapid and efficient genotyping owing to SNPs' simple structure as base changes.
Notwithstanding the novelty and promise of SNPs, there are uncertainties, especially in systematic genome-wide association (linkage disequilibrium) studies, of the sort mentioned earlier (see Association vs Linkage, above). First, the extent of linkage disequilibrium is highly variable across the genome, necessitating a whole-genome linkage disequilibrium map, to enhance the accuracy and efficiency of such studies. 151, 152 Second, even at high-density SNP mapping, many disease genes may escape detection because a negative linkage disequilibrium result (especially with nonexonic, or non-coding SNPs) does not rule out a significant gene effect in a particular genomic region. Third, because non-coding SNPs may be just as important as coding SNPs in the search for disease genes, hundreds of thousands of SNPs may be needed, 148, 151 with implications for the genotyping effort. Although this effort can be expedited by DNA pooling, the mapping effort is still substantial, with uncertainties about the accurate interpretation of SNP allele frequencies in various populations. 153 Fourth, as mentioned, the vast number of test results (tens of thousands to hundreds of thousands of SNPs, in thousands of subjects) raises questions about the statistical interpretation of the data, specifically the need to curtail false-positives due to multiple test effects. Genotyping cost is another consideration: at a rate of $0.50-1.00 per SNP, the cost of conducting a systematic genome-wide association study could range from tens of millions of dollars to well over $100 million, depending on the number of SNPs and subjects examined. New chip-based DNA technologies, or DNA microarrays, should speed-up the process and lower the cost, but cost-efficiency needs to improve by orders of magnitude, to render such efforts practicable.
Candidate markers A thorough genome screen may uncover all the genetic variations that contribute to the development of complex disorders such as BP. However, cost-efficiency can be improved by focusing on candidate gene markers (ie, testing alleles at polymorphic sites of physiological relevance). As mentioned (see Association Studies, above), the conventional candidate-gene strategy is fraught with difficulty. More systematic approaches are being developed. One such approach is the development of coding region-SNPs for all potential candidate genes for neuropsychiatric disease. This data base, which includes at present SNPs for hundreds of candidate genes (from among a pool of many thousands of potentially relevant genes), is still in its infancy 154, 155 but is steadily growing. Preliminary family-based linkage disequilibrium tests did not reveal clear evidence of association with BP. 155 The search can be made narrower by selecting candidate genes that are likely to play a role in BP, as opposed to neuropsychiatric disorders generally. Sorting out such genes is largely guesswork, informed, however, by plausible paradigms. For example, since BP is an episodic, cyclical condition, attention could be given to genes that govern biological systems involved in circadian and circannual clocks. Use of animal models (see also Animal Models, below) is another approach whereby a BP-like model is created, and genes that consequently show differential expression in brain are tagged as potential candidates. Similarly, differential gene expression due to drug treatment for BP (eg, lithium), or as a general screen of brain regions, 156 can also be used as a method for choosing potential candidate genes.
Whatever the strategy, confidence in a particular candidate is enhanced, if the putative gene resides in a genomic region already implicated in BP, usually through linkage studies. For example, Niculescu et al 157 used methamphetamine treatment of rats as an animal model for mania. Brain RNA was isolated for gene expression studies. One of the genes with the largest change in expression was GRK3, a G-protein receptor coupled kinase 3, which maps to 22q12, a region reportedly linked to BP (see Linkage Studies). A further example is Golf, the gene for a different G-protein, whose function is impaired by lithium. Golf maps to 18p11, another candidate gene for BP (see Linkage Studies), though subsequent studies showed no association with the illness (see The Phenotype). Conversely, genomic databases for chromosomal regions shown to be linked to BP can be searched for all plausible candidate genes in those regions, a task made easier by the Human Genome Project and SNP databases. Of course, potential candidates in regions with no evidence of linkage should not be ignored because some gene effects can elude detection by linkage analysis.
Molecular Psychiatry
Sample size
Assuming oligogenic inheritance (a plausible scenario for BP, as mentioned), several hundred affected sibpairs may be sufficient for detection of linkage. For example, under a 3-locus model and a genotypic relative risk of 8 (or 2 per locus), a sample of 300-400 sibpairs would be needed for adequate power, depending on the underlying assumptions. 3, 4, 114 Samples of this magnitude are not common in genome scans of BP, and are practically non-existent for BPI, the narrowest disease phenotype. The samples required to detect linkage to genes of more modest effect (relative risk Ͻ2) are much larger. 141, 142 A priori power calculations for extended pedigrees are less feasible because of the multiplicity of pedigree configurations. Estimates provided for published pedigree samples (see Linkage Studies), which range in size from a few families to several dozen pedigrees, point to low power under considerable heterogeneity; however, power may be adequate for genes of major effect. The samples required for replication of initial findings may be larger yet. 158 As mentioned, low power may lead to both type I (false-positive) and type II (false-negative) errors. This underscores the need for large data sets to firm up the evidence. Because sizable samples are rare, metaanalyses of several independent data sets can be conducted, in an attempt to elucidate gene effects.
The best-known meta-analysis of BP focused on chromosome 18. Linkage data were furnished by five independent groups, as part of Genetic Analysis Workshop (GAW) 10. Chromosome 18 was selected because of prior evidence of linkage to BP. 45, 48 The combined sample consisted of 2158 genotyped subjects, in 182 families. As summarized by Rice, 159 the results overall '% would appear suggestive, but not definitive,' in spite of the substantial sample size and the striking statistical significance in the original reports. 45, 48 A parallel meta-analysis, also by GAW10, focused on the dopamine transporter gene (DAT). DAT is a candidate gene for BP on chromosome 5, with some evidence of linkage 160 and linkage disequilibrium. 161 The combined sample for this analysis, comprised of five data sets, consisted of 1048 genotyped subjects in 95 families. The evidence for linkage to DAT was minimal. 159 There are potential drawbacks that limit the interpretation of meta-analyses. 162 These include methodological differences among samples (eg, ascertainment, diagnosis, marker density, and allele frequencies), reliance on the absolute linkage statistics (as opposed to ranking of chromosomal regions based on linkage signals), and selection bias that may skew the results-for example, the tendency to study more intensively (or treat preferentially) chromosomal regions with prior linkage evidence (as opposed to a more systematic approach), and the inclusion of the initial positive reports, which may be false-positive (a not infrequent event in psychiatric genetics). Interestingly, removal of the original reports of linkage to chromosome 18 45, 48 from the combined data would result in little, if any, evidence of linkage. New approaches to meta-analysis are being developed, in which some of the statistical issues are tackled. 163, 164 However, without a common, standardized protocol across studies, such analyses must be qualified.
As mentioned (see Association Studies), the two large meta-analyses of association studies with candidate genes-TH and TPH (401 and 927 cases, respectively, and their matched controls)-showed no evidence of significant association. Power estimates of the sample size needed for genome-wide association studies with SNPs, using case-control or family-based designs, suggest that thousands of subjects would be needed to detect modest gene effects. 141, 142 However, other investigators consider these estimates overly optimistic, especially in the presence of appreciable allelic heterogeneity. 144, 145 Several large-scale studies involving well-characterized clinical samples, systematic genome scans, and common research procedures are underway.
Population
Most gene mapping efforts are based on outbred populations. It has been proposed that the study of population isolates can enhance the prospects of linkage and association studies because isolated populations manifest fewer disease susceptibility alleles than the more heterogeneous outbred populations. As reviewed, 165 genome scans for several complex disorders, including essential hypertension, multiple sclerosis, schizophrenia, and BP, were conducted in population isolates, with some evidence of linkage. The relevant linkage findings for BP (see Linkage Studies) originated in genetic isolates from Canada (chromosome 12q23-24), 39 Costa-Rica (chromosome 18q22-23), 52 and Finland (chromosome Xq26). 65 Population isolates proved especially useful for joint linkage and association analysis of candidate genes for essential hypertension (the type 1 angiotensin II receptor gene) (see Association vs Linkage, above) and multiple sclerosis (the myelin basic protein gene), with substantial increase in statistical significance. 165 Simulations suggest that stable, isolated populations may be preferable to the more common, rapidly expanding population isolates (eg, Finland, Sardinia) with respect to mapping complex disease genes. 151 In concert with empirical data, 166 this implies that most population isolates may not be more useful for linkage studies of complex diseases such as BP than outbred populations. Indeed, genome scans of BP in population isolates have not shown a distinct advantage over studies of outbred populations by way of significance of results. Specifically, linkage results reported for population isolates (eg, the aforemetioned putative linkages between BP and 12q23-24, 18q22-23, and Xq26) were also found in samples drawn from general outbred populations (see Linkage Studies).
The utility of linkage disequilibrium mapping in large-scale SNP studies-as a function of the population studied-has been hard to assess because past studies have been basesd on only a few loci. A recent, systematic study of randomly selected genomic regions 167 suggests a two-tier approach: (1) Given cur- Taken together, the data suggest that the effectiveness of linkage mapping in complex diseases such as BP is not, by and large, population-dependent. In contrast, initial gene localization through linkage disequilibrium mapping may be more feasible in certain populations with a history of a strong founder effect. With further anticipated advances in SNP resources and technologies, and with greater understanding of population structure in various geographical regions, a larger array of populations may be amenable to this approach.
Multigene models
Although linkage studies to date might be consistent with locus heterogeneity-many genes, each of moderate-to-large effect, contributing to susceptibility to BP, much of the genetic variance is likely due to multiple genes with complex locus interactions. Consequently, standard statistical methods that treat disease loci as if they were independent of each other may not have sufficient power to detect genes of modest effect. [168] [169] [170] [171] [172] Novel methods that allow for the simultaneous consideration of multiple genomic regions are under consideration. For example, Cox et al 169 employed a locus interaction model to demonstrate that loci on chromosomes 2 and 15 increase susceptibility to diabetes (NIDDM1). Notably, in the initial genome scan, the linkage evidence for chromosome 15 was marginal, at best, using standard linkage analysis. This finding has subsequently led to the positional cloning of calpain-10 (CAPN10), a putative diabetes gene on chromosome 2.
170
More involved methods, which utilize neural networks, aim to identify sets of loci that jointly display evidence of linkage or association. By examining the inheritance of all markers jointly over the entire genome (eg, SNPs), these methods might be able to elucidate nonlinear relationships and interactions among the many disease loci that predispose to some complex disorders. [171] [172] [173] The data required for these analyses can be generated using microarray (DNA chip)-based technologies, and usually consist of thousands of cDNAs or oligonucleotides of interest.
Combining path analysis, segregation analysis, and linkage and association analyses is another method of interest. 174 This method may allow the systematic evaluation of multiple potential risk factors (both genetic and environmental) for interaction effects. Compared to most linkage and association methods, which examine a straightforward genotype-phenotype relationship, the information extracted from family data using this approach is more comprehensive, with implications for the detection of genes of small effect.
These, and other multigenic methods, are still being developed and have yet to be applied to BP.
Lessons from other disorders
Lessons learned from other complex disorders can be instructive. For example, the successful identification by linkage analysis of mendelian subsets-Alzheimer disease (beta-amyloid precursor protein and presenilin -1 and -2), breast cancer (BRCA-1 and -2), colon cancer (familial adenomatous polyposis and hereditary non-polyposis colorectal cancer), diabetes (maturityonset diabetes of youth), and heart disease (LDL receptor gene)-may pave the way for similar developments in other complex diseases. Although the mutated genes are rare (mendelian inheritance accounts for a small minority of affected cases, at best), they are more readily tractable than genes of modest effect and may, eventually, contribute to our knowledge of more common forms of these disorders.
Another example is APOE, a disease allele which increases susceptibility to a common form of Alzheimer's disease (as opposed to the rare, mendelian type mentioned earlier), and which was identified by linkage mapping (though the presence of association may have increased the power to detect it). 140 The discovery of the role of APOE in Alzheimer's disease was facilitated by the observation that it also predisposes to cardiovascular disease, another common non-mendelian condition.
There are two other examples worth mentioning. Tsao et al 175, 176 reported linkage between systemic lupus erythematosus (SLE) and chromosome 1q41-42, following a clue from mouse models of SLE, which pointed to the homologous chromosomal region. Subsequently, the authors showed significant linkage disequilibrium between SLE and PARP, a candidate gene in the linkage confidence interval, which also shows reduced levels of expression in SLE patients. Tavtigian et al 177 reported the cloning of a putative prostate cancer susceptibility gene, ELAC2, located on chromosome 17p11. Initially, these investigators found linkage between the disease and 17p11. Although the evidence of linkage was weakened appreciably upon expansion of the original data set, the investigators pursued this line of investigation, ascribing the diminished evidence to heterogeneity. They focused on families with a common 17p11 haplotype in several cases, including families with no evidence of linkage due to many noncarrier cases. In the region of shared overlap, they identified the ELAC2 gene, which encodes an evolutionary conserved domain, with repair functions conMolecular Psychiatry sistent with a potential involvement in susceptibility to cancer. These findings await replication.
What lessons can be learned from these studies? First, the fact that mendelian subsets were identified by clinical and biological covariates (early onset in Alzheimer's disease, breast cancer and diabetes, and LDL in heart disease), and that APOE plays a role in both Alzheimer's disease and cardiovascular disease, affirms the importance of phenotype definition (or conjectures from other disease phenotypes) in genetic analysis of complex traits such as BP. As mentioned (see The Phenotype, above), potential applications to BP may include dissection of the phenotype using clinical characteristics such as treatment response (responders vs non-responders), age at onset (early vs late), co-morbidity (presence or absence of other disease states or syndromes), and course of illness (eg, high-frequency vs low-frequency episodes), or biological endophenotypes such as varying degrees of neuropsychological, neuroimaging or neuroanatomical aberrations. If successful, phenotype refinement could augment the signal-to-noise ratio in the detection of gene effects.
Second, the positional cloning of CAPN10, the diabetes candidate gene, underscores the potential utility of locus interaction models in complex disease (see Multigene Models, above). Such models have yet to be tested systematically in BP.
Third, notwithstanding conflicting linkage results in SLE and prostate cancer, progress on candidate genes, however provisional, holds promise for other complex disorders. For example, the use of a mouse model of SLE to generate linkage evidence in man, followed by the identification of a candidate gene in the linked region, could inform animal models of BP. Indeed, the methamphetamine-induced rat model of mania, which led to GRK3, a potential candidate gene in a region possibly linked to BP (see Candidate Markers, above), follows a similar logic (see also Animal Models, below).
Fourth, the unconventional approach taken in the prostate cancer study-specifically, the pursuit of hints from haplotype patterns with no formal statistical justification-points to the potential merit of 'intuitive' approaches in the search for complex disease genes. The analogy to BP is not far-reaching. There are numerous accounts of linkage signals, which are not universally accepted, show a nonuniform haplotype pattern in 'linked' pedigrees and, moreover, are weakened by expansion of the original data set. Following the lead of the prostate cancer study, such findings need not be discarded, especially if potential clues to the disease are in evidence (eg, a promising candidate gene).
Animal models
Animal models will likely play a major role in the genetic dissection of complex disorders. For example, the close homology between many mouse and human gene sequences (maintaining the same order of genes, in many instances), and the rapidly evolving data sets for human-mouse synteny, underscore the utility of mouse models of disease. Some obvious applications include: (1) A search for a conserved synteny region from among human chromosomal regions suspected of harboring disease genes, followed by sequencing and identification of the mutated gene. The relevance of animal models for complex human disorders has been demonstrated by comparative animal-human genomics. For example, translating candidate genes between rat and human has resulted in several chromosomal regions in the human genome (some of these regions have also been implicated in the mouse), with very high likelihood of harboring genes for hypertension. 178 Of course, mouse and rat models are not well suited for elucidating genes involved in psychiatric disease. However, mouse genes for behavioral abnormalities with possible human analogues have been reportedfor example, 'emotionality' 179 and fear-conditioning. 180 Also, some behavioral phenotypes that cut across species may have relevance for BP-for example, circadian and circannual rhythms, and methamphetamineinduced manic-like behavior, in mouse models (see Candidate Markers, above). Most importantly, the recently completed whole-genome linkage map of the baboon, a nonhuman primate, using primarily human microsatellite markers and displaying high-level conservation of locus order, 181 presents important new opportunities for the study of human diseases with no corresponding models in lower species. Plans to sequence the genome of other nonhuman primates, in particular the chimpanzee, should further this line of investigation.
It should be noted, of course, that the utility of animal models is largely confined to the initial detection and functional analysis of human disease genes. The ultimate proof for the role of these genes in human disease would require large-scale epidemiological studies, to determine if allelic variation at the sequenced genes could be causally related to the disease being studied. Also, since genetic susceptibility in most common human diseases may be largely due to naturally occurring variation in multiple genes, as opposed to gross genomic interruptions such as gene deletion, the utility of certain animal models, such as knockout and transgene, has its limits.
Bioinformatics
The Human Genome Project and its myriad spinoffs are generating vast amounts of raw sequences, polymorphisms, and gene expression data for thousands of genes. The effective integration, interpretation and application of this information will require powerful computational tools. There are many reasons for embarking on this venture: (1) Much of the information is not readily available for computerized analysis, requiring automated methods for mining free-text forms and other resources. (2) Making the data available publicly, in a readily accessible form, will facilitate cross-validation of findings produced by different methods, and will enable the establishment of gold statndards. (3) Microarray analysis may lead to the discovery of previously unknown genes, based on similarities in expression profiles with other genes. (4) Multigene analytical methods, which may be pivotal to genetic studies of complex disorders such as BP (see Multigene Models, above), will be greatly aided by computerized databases on comprehensive arrays of genes and gene expression.
The development of definitive bioinformatics tools is at an early age, but strides toward achieving this goal are in evidence. For example, Masys et al 182 described a data mining method for extracting information on gene clusters and expression based on the published literature. Similarly, Jenssen et al 183 developed an analytical approach to searching MEDLINE citations for the presence of gene identifiers, which were then used to establish a network of relationships among genes. It is expected that the utility of such methods will improve as the search tools gain in power and robustness, and as the published literature gains in scope and electronic accessibility.
Conclusion and outlook
Multiple candidate regions are implicated in the genetic susceptibility to BP-in particular, 1q31-32, 4p16, 6pter-p24, 10p14, 10q25-26, 12q23-24, 13q31-32, 18p11, 18q21-23, 21q22, 22q11-13, and Xq24-28. Findings pertaining to these regions appear to meet minimal criteria for genome-wide statistical significance and are supported by independent studies. However, the prospects of imminent gene discovery are qualified by myriad factors including conflicting results, relatively small samples with low power to avert type 1 and type 2 errors, large linkage intervals that complicate positional cloning, absence of a full complement of potential candidate genes and polymorphisms, and critical analytical tools that are not fully developed. More definitive efforts are underway:
(1) Collection of large, well-characterized data sets (pedigrees and population-based samples), including comprehensive phenotypic information and cell lines for DNA extraction. (2) Systematic, whole-genome marker-intensive searches for linkage and linkage disequilibrium, using the ever-expanding archive of markers and candidate genes, from both human and comparative genomics. (3) Continued development and application of advanced molecular technologies (eg, DNA-chip methods, DNA pooling, and high-speed SNP testing), to facilitate genome-wide studies. (4) Continued development and application of analytical and computational tools for the processing, analysis and interpretation of genetic data.
These large-scale efforts, which require collaborations among clinicians, molecular biologists, epidemiologists, statisticians, and bioinformatics experts, need not negate more circumscribed, follow-up studies of interesting clues from existing data, which may yet yield promising findings.
